One of the highest priorities of the Simmons Cancer Center is to efficiently translate scientific discoveries to the clinic in order to reduce cancer morbidity and mortality. U.T. Southwestem has a long tradifion of excellence in the basic sciences and with the recent organizafion of well-defined Cancer Center programs, insfitufional scienfists are responsible for some of the most important recent advances in translatable cancer biology. Early phase Invesfigator-inifiated translafional research trials require significant regulatory, data management and research nursing resources that are not always available through traditional mechanisms in a fimely fashion. Protocol-specific research support provides a mechanism for rapidly translating insfitutional cancer science to the clinic. These funds are intended to support the programmatic priorifies of the Simmons Cancer Center. Criteria used to assess suitability for Protocol-Specific Research support include: 1. Invesfigator-initiated feasibility/Phase I or pilot trial with exceptional scientific merit 2. The trial must meet one or more of the following criteria: a. The agent or concept to be tested is a product of U.T. Southwestern preclinical science. b. The trial will generate data required for external peer-reviewed funding or for development into a larger, multi-institutional phase II or III trial. c. The trial promotes significant interacfion between basic and clinical scienfists to achieve important correlative objecfives. Priorities for this funding are communicated to the Disease Oriented Teams (DOTs) through the bi-monthly DOT leaders meetings and to the Program Leaders at their bi-monthly meefings. Information flows both direcfions at these meefings as DOT leaders can vet invesfigator inifiated protocol ideas and Program leaders can promote agents or molecules ready for clinical evaluafion. Individual DOTs are encouraged to develop and refine protocol concepts responsive to the Cancer Center priorifies and to seek feedback from the Associate Director for Clinical Research early in the development process.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA142543-03
Application #
8380785
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
3
Fiscal Year
2012
Total Cost
$16,276
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Eskiocak, Banu; McMillan, Elizabeth A; Mendiratta, Saurabh et al. (2017) Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov 7:832-851
Rutkowski, Joseph M; Pastor, Johanne; Sun, Kai et al. (2017) Adiponectin alters renal calcium and phosphate excretion through regulation of klotho expression. Kidney Int 91:324-337
Singh, Jaspal; Rustagi, Vineeta; Zhang, Shanrong et al. (2017) On-bead combinatorial synthesis and imaging of europium(III)-based paraCEST agents aids in identification of chemical features that enhance CEST sensitivity. Magn Reson Chem 55:747-753
Singh, Dinesh K; Kollipara, Rahul K; Vemireddy, Vamsidara et al. (2017) Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma. Cell Rep 18:961-976
Gu, Yi-Feng; Cohn, Shannon; Christie, Alana et al. (2017) Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. Cancer Discov 7:900-917
Lee, Ming Y; Sumpter Jr, Rhea; Zou, Zhongju et al. (2017) Peroxisomal protein PEX13 functions in selective autophagy. EMBO Rep 18:48-60
Gao, Boning; Huang, Chunxian; Kernstine, Kemp et al. (2017) Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 8:11114-11126
Howard, James J; Sturge, Carolyn R; Moustafa, Dina A et al. (2017) Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers. Antimicrob Agents Chemother 61:
Skinner, Celette Sugg; Ahn, Chul; Halm, Ethan A et al. (2017) Recommendation of colorectal cancer testing among primary care patients younger than 50 with elevated risk. Prev Med 102:20-23
Garcia, Sandra; Bisen, Ajit; Yan, Jingsheng et al. (2017) Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. J Thorac Oncol 12:1489-1495

Showing the most recent 10 out of 441 publications